KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer
A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of KN046 Combined With Platinum-containing Chemotherapy Versus Placebo Combined With Platinum-containing Chemotherapy in First Line Advanced Squamous Non-small Cell Lung Cancer Subjects (ENREACH-L-01)
Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
This PHASE3 trial investigates Squamous Non-small-cell Lung Cancer and is currently ongoing. Jiangsu Alphamab Biopharmaceuticals Co., Ltd leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Dec 2023 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Dec 2021 — Dec 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Dec 2021 [monthly]
Recruiting PHASE3
▶ Show 2 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Aug 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .